<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785976</url>
  </required_header>
  <id_info>
    <org_study_id>KY 2020-11-26</org_study_id>
    <nct_id>NCT04785976</nct_id>
  </id_info>
  <brief_title>Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <acronym>LongTEAM</acronym>
  <official_title>Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage: an MDT- Based Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University International Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a&#xD;
      potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At&#xD;
      present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for&#xD;
      aneurysmal subarachnoid hemorrhage (aSAH), in recent years, the improvements in surgical&#xD;
      equipment and techniques have already greatly improved the postoperative safety of patients.&#xD;
      However, considering individual differences between patients, some still at risk due to&#xD;
      possible complications during hospitalization or after discharge from the hospital, it will&#xD;
      no doubt generate a large healthcare burden.&#xD;
&#xD;
      This prospective, observational clinical trial (LongTEAM) is to improve the diagnosis and&#xD;
      treatment effect and efficiency in this field, reducing mortality, medical costs, and medical&#xD;
      burden, while opening up new avenues for interdisciplinary clinical practice and scientific&#xD;
      research exploration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2012</start_date>
  <completion_date type="Anticipated">April 1, 2032</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2032</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Unfavorable neurological outcome (mRS&gt;2)</measure>
    <time_frame>10 days after the procedure</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at discharge, defined as a modified Rankin Scale (mRS) score of &gt;2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unfavorable neurological outcome (mRS&gt;2)</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 3 months post-treatment, defined as a modified Rankin Scale (mRS) score of &gt;2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unfavorable neurological outcome (mRS&gt;2)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 6 months post-treatment, defined as a modified Rankin Scale (mRS) score of &gt;2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unfavorable neurological outcome (mRS&gt;2)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 12 months post-treatment, defined as a modified Rankin Scale (mRS) score of &gt;2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unfavorable neurological outcome (mRS&gt;2)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 24 months post-treatment, defined as a modified Rankin Scale (mRS) score of &gt;2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive deficits</measure>
    <time_frame>10 days after the procedure</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at discharge,defined as changes in thinking, emotion, will and behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive deficits</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 3 months, defined as changes in thinking, emotion, will and behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive deficits</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 6 months, defined as changes in thinking, emotion, will and behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive deficits</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 12 months, defined as changes in thinking, emotion, will and behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive deficits</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients experiencing a unfavorable neurological outcome at 24 months, defined as changes in thinking, emotion, will and behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac or cerebrovascular events</measure>
    <time_frame>10 days after the procedure</time_frame>
    <description>Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac or cerebrovascular events</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac or cerebrovascular events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac or cerebrovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac or cerebrovascular events</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 24 months.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Surgical clipping</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovascular coiling</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical clipping and endovascular coiling</intervention_name>
    <description>Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coilingï¼šAlso called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.</description>
    <arm_group_label>Endovascular coiling</arm_group_label>
    <arm_group_label>Surgical clipping</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to the emergency department of the investigator with aneurysmal&#xD;
        subarachnoid hemorrhage are included in their prospective registry&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients admitted to the emergency department of the investigator with aneurysmal&#xD;
             subarachnoid hemorrhage are included in their prospective registry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fa Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuanli Zhao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jizong Zhao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Runting Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolin Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junlin Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhipeng Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heze Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Debin Yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shuo Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Runting Li, MD</last_name>
    <phone>+8615753166690</phone>
    <phone_ext>+8613681107240</phone_ext>
    <email>1011168227@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaolin Chen, MD</last_name>
    <phone>+8613810624845</phone>
    <phone_ext>+8615753166690</phone_ext>
    <email>xiaolinchen488@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Runting Li, MD</last_name>
      <phone>+8615753166690</phone>
      <email>1011168227@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaolin Chen, MD</last_name>
      <phone>+8613810624845</phone>
      <email>xiaolinchen488@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>yuanli Zhao</investigator_full_name>
    <investigator_title>Director of Department of Cerebrovascular Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The individual participant data (IPD) of this study are available from the principal investigator upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>6 months after the study ended</ipd_time_frame>
    <ipd_access_criteria>The IPD of this study are available from the principal investigator upon reasonable request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

